Impaired serum neutralization and death in Omicron-infected critically ill patients: insights from the French SEVARVIR prospective, multicenter cohort study
Authors:
Open Access
- 26 November 2025
- journal article
- research article
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 13 (1) , 121
Abstract
Background: Despite advances in treatment, critically ill COVID-19 patients requiring intensive care unit (ICU) admission continue to comprise a substantial proportion of cases. However, the factors influencing poor prognosis in this population remain poorly understood. To address this knowledge gap, we conducted a prospective analysis of serum neutralizing activity against SARS-CoV-2 in 49 non-selected, critically ill COVID-19 patients enrolled in the multicenter SEVARVIR cohort between October 2022 and May 2024. Methods: This a substudy of the SEVARVIR prospective multicenter observational cohort study (NCT05162508). We included 49 critically ill COVID-19 patients hospitalized in four French intensive care units between October 2022 and May 2024 from the 827 patients enrolled in the multicenter, prospective SEVARVIR study. Serum neutralizing titers of authentic SARS-CoV-2 isolates were measured using the S-Fuse assay and patients categorized as neutralizers if they had an anti-spike serum neutralization titer against the infecting variant > 15 and non-neutralizers if ≤ 15. Full-length SARS-CoV-2 genomes from all included patients were sequenced by means of next-generation sequencing. Results: Median age was 73 years (59–75) and 34.7% of patients ( n = 17/49) were female. Half of the patients (53.1%, n = 26/49) had immunosuppressive comorbidities. A large proportion of individuals lacked the capacity to neutralize their infecting variant (57.1%, n = 28/49). Neutralizing titers were significantly higher in 28-day survivors than in deceased patients (p = 0.0212) and neutralizers had a significantly lower 28-day mortality than non-neutralizers (5.0%, n = 1/21 vs. 32.1%, n = 9/28; p = 0.0312). Nine out of the ten patients who succumbed to the disease within 28 days of admission had undetectable serum neutralizing capacity, which was significantly more prevalent than in survivors ( p = 0.03), irrespective of immunosuppression status. The sole patient who died despite having detectable neutralizing antibodies against SARS-CoV-2, was found to have anti-interferon auto-antibodies. Conclusion: These findings underscore the potential benefits of early therapeutic interventions aimed at enhancing neutralization, which may improve survival outcomes in both immunocompetent and immunocompromised critically ill COVID-19 patients.Keywords
Funding Information
- EMERGEN consortium—ANRS Maladies Infectieuses Emergentes (ANRS0153)
- French Foundation for Medical Research (EA20170638020)
- French National Agency of Research (ANR-23-CE15-0039-01)
This publication has 22 references indexed in Scilit:
- mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functionsScience Translational Medicine, 2022
- Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deathsScience Immunology, 2021
- Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2npj Vaccines, 2021
- Delayed production of neutralizing antibodies correlates with fatal COVID-19Nature Medicine, 2021
- Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesNature Medicine, 2021
- Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19New England Journal of Medicine, 2021
- COVID-19-neutralizing antibodies predict disease severity and survivalCell, 2021
- Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19Blood, 2020
- Complex heatmaps reveal patterns and correlations in multidimensional genomic dataBioinformatics, 2016
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996